“ApoB predicts heart risk better than LDL cholesterol.”
ApoB predicts heart and artery disease risk more accurately than LDL cholesterol, especially when the two results do not match.
ApoB is a sharper measure of heart risk than LDL cholesterol for some people, but most people do not need the extra test. A standard cholesterol panel plus your other risk factors still answers the main question.
At your next cholesterol check, ask whether an apoB result would change any decision in your situation.
Safety note: ApoB is one risk marker, not a diagnosis or a reason to change treatment by itself. Decisions should include blood pressure, smoking, diabetes, kidney disease, family history and overall cardiovascular risk.
Talk to a healthcare professional if: your triglycerides are high, you have diabetes or metabolic syndrome, heart disease came early in your family, or your LDL result seems out of line with your overall risk. Ask whether an apoB test would change your treatment.
Moderate confidence because apoB counts the harmful cholesterol-carrying particles, and a large prospective study found apoB kept predicting risk when LDL cholesterol did not. Most people have matching values, the key comparisons are observational, and major guidelines still use LDL cholesterol as the main treatment marker.
ApoB predicts heart and artery disease risk more accurately than LDL cholesterol, especially when the two results do not match. LDL cholesterol remains a useful, widely used marker, and for most people the two point the same way.
Each artery-clogging particle carries one apoB molecule, while LDL cholesterol measures the cholesterol inside LDL particles. The same LDL cholesterol can therefore reflect different particle numbers. ApoB adds the most when triglycerides are high, diabetes or metabolic syndrome is present, or results do not fit the overall picture.
- De Oliveira-Gomes D, Joshi PH, Peterson ED, Rohatgi A, Khera A, Navar AM. Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice. Circulation. 2024;150(1):62-79. DOI: 10.1161/CIRCULATIONAHA.124.068885. PMID: 38950110. PMCID: PMC11219008
- Sniderman AD, Dufresne L, Pencina KM, et al. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. European Heart Journal. 2024;45(27):2410-2418. DOI: 10.1093/eurheartj/ehae258. PMID: 38700053. PMCID: PMC11242442